Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has taken a significant step toward securing additional funding by executing a term sheet with arm's-length institutional investors for a non-brokered private placement. The offering, with a notional subscription amount of approximately CAD$5 million, consists of 6,764,070 units at a notional price of CAD$0.7392 per unit. Each unit comprises one common share and one common share purchase warrant. The financing is expected to close on or about July 15, 2026, subject to customary conditions and regulatory approvals.
The company intends to use the net proceeds to support the development of its ONC010 program, including manufacturing and preclinical testing activities, as well as to advance its SynoGraph platform and for general working capital. This funding is critical for Onco-Innovations as it progresses its oncology-focused pipeline, which targets solid tumors through patented technology for which the company holds an exclusive worldwide license.
Under the proposed structure, the company's economic interest will be determined through 18 monthly settlement tranches based on the future trading price of its shares. Additional details regarding the placement will be provided upon closing. This approach allows the company to align investor returns with its share performance over time.
The announcement underscores Onco-Innovations' commitment to advancing cancer research and treatment. By securing this funding, the company aims to accelerate its preclinical and manufacturing activities, potentially bringing its innovative therapies closer to clinical trials. For investors and the biotechnology industry, this development signals continued momentum in Onco-Innovations' efforts to address unmet needs in oncology.
Further information about the company and its latest news is available in its newsroom at https://ibn.fm/ONNVF. The full press release regarding the private placement can be accessed at https://ibn.fm/y3hsM.
